Press Coverage

From Concept to Clearance: Why It's So Expensive to Develop New CV Drugs

Article about a JAMA study showing new cardiovascular drugs are developed at a cost more than 100-fold higher than the average refers to a paper co-authored by ISMP's senior scientist, Thomas Moore, that examined expenses associated with clinical trials and the factors that contribute to those costs.

For the full text, visit Cardiovascular Business online.


More News

Since the 2021-2022 influenza (flu) vaccine became available in September, the Institute for Safe Medication Practices (ISMP) has received multiple reports of mix-ups. Some patients have consented to a flu vaccine but received one of the COVID-19 vaccines instead, while others have received the flue